Module 5

Will immune checkpoint inhibitors deliver in myeloma?

About this module

Dr Rakesh Popat describes the mechanisms of immune checkpoints in T cell activity and discusses their role as potential therapeutic targets in myeloma.

Dr Popat is a Clinical Fellow supported by the National Institute for Health Research, University College London Hospitals Biomedical Research Centre.

CPD hours: 1

References

Pardoll N. (2012) The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12: 252-264.

Garfall A et al. (2013) Cellular immonotherapy for plasma cell myeloma. Bone Marrow Transplant. 48: 1377-1386.

Sznol M et al. (2013) Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer. Clin. Cancer Res. 19: 1021-1034.

Gorgun G et al. (2015) Lenalidomide enhances immune checkpoint blockade-induced immune response in multiple myeloma. Clin. Cancer Res. 21: 4607-4618.

Suen H et al. (2016) Multiple myeloma causes clonal T-cell immunosenescence: identification of potential novel targets for promoting tumour immunity and implications for checkpoint blockade. Leukemia 30: 1716-1724.

Lesokhin A et al. (2016) Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a Phase 1b study. J Clin. Oncol. 34: 2698-2704.

Michot J et al. (2016) Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer 54: 139-148.

Take the CPD Quiz